Bristol goes pivotal with SystImmune-partnered conjugate
The first global pivotal trial will be in first-line triple-negative breast cancer.
J&J broadens its bladder cancer push
TAR-210's latest non-muscle invasive bladder cancer phase 3 setting is post-BCG.
Xencor could face second challenge from former partner
J&J's new anti-ENPP3 ADC appears – and then disappears – from a clinical study listing.
BridgeBio enters the pan-KRAS game
Meanwhile, Akeso challenges Moderna and BioNTech with an mRNA neoantigen play.
MAIA throws more money at ateganosine
The THIO-104 study listing is live, along with questions about funding the trial.
Head and neck cancer is next for evorpacept
Against the odds, the CD47 inhibitor now faces two more clinical catalysts.
